

**Sample Chapter 4(C) Health Certificate  
For the Export of Ruminant Blood Products  
Directly to Approved EU Facilities in the EU for Further Processing**

If a facility is exporting ruminant origin materials from an area not recognized as free of BT and VSV (and not vaccinating for these diseases), and the materials have not been processed and safety tested in accordance with Regulation (EC) 1774/2002, then section II.4 of the Chapter 4(C) Health Certificate must be completed as indicated below (stricken sections must be initialed by the endorser).

(<sup>2</sup>) either [II.4. in the case of blood products derived from ruminant animals they originate in a third country or regions, where:

~~(<sup>2</sup>) either [the animals and products come from a region where no case of foot-and-mouth disease, vesicular stomatitis, rinderpest, peste des petits ruminants, Rift Valley fever and bluetongue (<sup>3</sup>) has been recorded for 12 months and in which vaccination has not been carried out against those diseases for at least 12 months and from which imports of ruminant animals are authorized pursuant to Community legislation. The blood from which such products are manufactured must have been collected.]~~

(<sup>2</sup>) either [in slaughterhouses approved in accordance with Community legislation;]

(<sup>2</sup>) or [from live animals in facilities approved in accordance with Community legislation;]

~~(<sup>2</sup>) or [in slaughterhouses approved and supervised by the competent authority of the third country. In this case the Commission and Member States must be notified of the address and approval number of such slaughterhouse and the certificate shall indicate this information;]~~

(<sup>2</sup>) or [the products have undergone one of the following treatments, guaranteeing the absence of pathogens of the ruminant diseases foot-and-mouth disease, vesicular stomatitis, rinderpest, peste des petits ruminants, Rift Valley fever and bluetongue (<sup>3</sup>):

(<sup>2</sup>) either [heat treatment at a temperature of 65 °C for at least three hours, followed by an effectiveness check;]

(<sup>2</sup>) or [irradiation at 2,5 megarads or by gamma rays, followed by an effectiveness check;]

(<sup>2</sup>) or [change in pH to pH 5 for two hours, followed by an effectiveness check;]

~~(<sup>2</sup>) or [heat treatment of at least 90 °C throughout their substance, followed by an effectiveness check;]~~

(<sup>2</sup>) or [sero-positive bluetongue animals are present, and the blood products are intended for technical purposes including pharmaceuticals, in vitro diagnosis and laboratory reagents, to be processed in the approved plants [approval number] in [Member State] (<sup>4</sup>);]

**Export certificates must have an approval number noted where the above has [approval number]. This number must be the number of the approved facility in the EU, and must correspond to a number included on the U.S. facility's approved Notarized Processing Method Form. APHIS does not verify that the number is correct, only that it corresponds to a number on the U.S. facility's approved Notarized Processing Method Form.**

Only when the Chapter 4(C) Health Certificate is completed as noted above, may blood products not either originating from areas meeting the disease/vaccine freedom requirements, or treated under the required parameters, be exported to the EU.